Tech Company Financing Transactions

Targanta Therapeutics Funding Round

On 2/12/2007, Targanta Therapeutics secured $70 million in Series C financing from Brookside Capital, OrbiMed and Skyline Ventures.

Transaction Overview

Company Name
Targanta Therapeutics
Announced On
2/12/2007
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series C
Investors

Brookside Capital (Lead Investor) (Jay Venkatesan)

OrbiMed (Lead Investor)

Skyline Ventures (Lead Investor) (Eric Gordon)

Canadian Medical Discoveries Fund

Radius Ventures

Seaflower Ventures

Vengrowth Asset Management (Jeffrey Courtney)

Proceeds Purpose
The company intends to utilize this capital to prepare and submit the New Drug Application (NDA) for its lead product, oritavancin, for the treatment of complicated skin and skin structure infections (cSSSI). Targanta expects to file the NDA in the second half of 2007. In addition, the Series C will help fund new oritavancin clinical trials in pneumonia, bacteremia and single dose treatment for cSSSI.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
222 Third St. 2300
Cambridge, MA 02142
USA
Phone
(617) 577-9020
Website
www.targanta.com
Email Address
[email protected]
Overview
Targanta Therapeutics is a privately held biopharmaceutical company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Its pipeline includes an array of antibacterial agents in various stages of development.
Profile
Targanta Therapeutics LinkedIn Company Profile
Social Media
Targanta Therapeutics Company Twitter Account
Company News
Targanta Therapeutics News
Facebook
Targanta Therapeutics on Facebook
YouTube
Targanta Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Leuchtenberger
  Mark Leuchtenberger LinkedIn Profile  Mark Leuchtenberger Twitter Account  Mark Leuchtenberger News  Mark Leuchtenberger on Facebook
Chief Financial Officer
George Eldridge
  George Eldridge LinkedIn Profile  George Eldridge Twitter Account  George Eldridge News  George Eldridge on Facebook
Chief Scientific Officer
Thomas Parr
  Thomas Parr LinkedIn Profile  Thomas Parr Twitter Account  Thomas Parr News  Thomas Parr on Facebook
Vice President
Susan Hager
  Susan Hager LinkedIn Profile  Susan Hager Twitter Account  Susan Hager News  Susan Hager on Facebook
Vice President
Margaret Wasilewski
  Margaret Wasilewski LinkedIn Profile  Margaret Wasilewski Twitter Account  Margaret Wasilewski News  Margaret Wasilewski on Facebook
VP - Finance
Christian Belisle
  Christian Belisle LinkedIn Profile  Christian Belisle Twitter Account  Christian Belisle News  Christian Belisle on Facebook
VP - General Counsel
Daniel Char
  Daniel Char LinkedIn Profile  Daniel Char Twitter Account  Daniel Char News  Daniel Char on Facebook
VP - Human Resources
Stanley Merrill
  Stanley Merrill LinkedIn Profile  Stanley Merrill Twitter Account  Stanley Merrill News  Stanley Merrill on Facebook
VP - Marketing
Gayle Fischer
  Gayle Fischer LinkedIn Profile  Gayle Fischer Twitter Account  Gayle Fischer News  Gayle Fischer on Facebook
VP - Operations
Roger Miller
  Roger Miller LinkedIn Profile  Roger Miller Twitter Account  Roger Miller News  Roger Miller on Facebook
VP - Regulatory Affairs
William Current
  William Current LinkedIn Profile  William Current Twitter Account  William Current News  William Current on Facebook
VP - Sales
Ron Wickline
  Ron Wickline LinkedIn Profile  Ron Wickline Twitter Account  Ron Wickline News  Ron Wickline on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/9/2007: RiverGlass venture capital transaction
Next: 2/12/2007: Dashwire venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to document all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.